ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials

Abdel-Rahman Omar

首页> 外文期刊>International journal of colorectal disease. >ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials

【24h】

ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials

机译：ECOG性能评分0与1：对五行5-Fu的化疗的影响，转移结直肠癌患者包括五种随机试验中的患者

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Within the context of metastatic colorectal cancer, patients with Eastern Cooperative Oncology Group (ECOG) performance score 0-1 are usually pooled together in clinical practice guidelines and clinical trials' reports. The current study aims to delineate potential differences in outcomes between metastatic colorectal cancer patients with ECOG score 0 versus 1 who are treated with currently accepted first-line fluorouracil (5FU)-based chemotherapy.

机译：背景技术在转移性结肠直肠癌中，东方合作肿瘤学群（ECOG）性能评分0-1的患者通常在临床实践指南和临床试验的报告中共同汇集在一起。目前的研究旨在描绘转移性结直肠癌患者eCOG评分患者的潜在差异0与当前接受的一线氟尿嘧啶（5Fu）的化疗治疗。

著录项

来源
《International journal of colorectal disease.》 |2019年第12期|共8页
作者
Abdel-Rahman Omar;
展开▼
作者单位

Univ Alberta Cross Canc Inst Dept Oncol Edmonton AB T4G 1Z2 Canada;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词
ECOG; Performance; Efficacy; Toxicity; Outcomes;

机译：ECOG;性能;疗效;毒性;结果;
入库时间 2022-08-20 02:07:21

相似文献

外文文献
中文文献
专利

1. ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials [J] . Abdel-Rahman Omar International journal of colorectal disease. . 2019,第12期

机译：ECOG性能评分0与1：对五行5-Fu的化疗的影响，转移结直肠癌患者包括五种随机试验中的患者
2. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials [J] . Abdel-Rahman Omar Clinical colorectal cancer . 2019,第4期

机译：体重指数对转移结直肠癌患者5富基化疗毒性和功效的影响; 汇总分析5次随机试验
3. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer [J] . Y. Bécouarn1 P. Senesse2 S. Thézenas2 E. Boucher3 A. Adenis4 L. Cany5 J. H. Jacob6 F. Cvitkovic7 C. Montoto-Grillot8 and M. Ychou2 Annals of Oncology . 2007,第12期

机译：一项II期随机试验，评估一线转移性结直肠癌的实验性化疗方案（伊立替康+奥沙利铂，IRINOX）和两个标准组（LV5-FU2 +伊立替康或LV5-FU2 +奥沙利铂）的安全性和有效性：中央国家癌症中心消化小组
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
6. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational randomized non-inferiority phase III trial of second-line chemotherapy for metastatic colorectal cancer comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab [O] . Masahito Kotaka, Ruihua Xu, Kei Muro, 2016

机译：亚洲XELIRI ProjecT（AXEPT）的研究方案：一项针对转移性结直肠癌的二线化疗的跨国非劣效非劣效性三期临床试验比较了XELIRI联合或不联合贝伐单抗与FOLFIRI联合或不联合贝伐单抗的疗效和安全性
7. Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) [O] . T.W. Kim, Y.S. Park, K. Muro, 2017

机译：转移性结肠直肠癌二线化疗的随机，非劣等，III期试验（MCRC），比较Xeliri + Bevacizumab的疗效和安全性与Folfiri + Bevacizumab（Axept）

ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials

摘要

著录项

相似文献

相关主题

期刊订阅